<DOC>
	<DOCNO>NCT01505153</DOCNO>
	<brief_summary>This Phase I safety trial bifunctional shRNA-STMN1 ( pbi-shRNA™STMN1 ) BIV ( bilamellar invaginate vesicle ) lipoplex ( LP ) , pbi-shRNA™ STMN1 LP administer single intratumoral ( IT ) injection . Patients superficially accessible advanced cancer follow prior therapy enter study follow modify dose escalation design base demonstrate safety previous clinical experience ( BB-IND 13744 ) liposome vector DNA backbone express different transgene ( dose 7 mg DNA IV/single dose administer ) . Patients accrue 4-patient escalation cohort use modified Fibronacci escalation schema ( 100 % -50 % -33 % -33 % ) start intratumoral dose 0.010 mg/kg DNA dose 0.053 mg/kg DNA intratumoral / single dose . Should single , two ( 2 ) , ≥ Grade 3 Dose Limiting Toxicity ( DLT ) occur cohort , follow mandate review ( see ) additional two ( 2 ) patient accrue dose ( total six ) . If one ≥ Grade 3 toxicity occur cohort , precede dose cohort expand six ( four ) &lt; 2/6 patient experience ≥ Grade 3 toxicity , dose Phase II recommend dose . Should ≥ Grade 3 toxicity occur cohort ( Grade 3 local injection site reaction ) , additional two ( 2 ) patient treat 0.053 mg/kg DNA intratumoral / single dose .</brief_summary>
	<brief_title>Phase I Intratumoral Pbi-shRNA STMN1 LP Advanced and/or Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>1 . Histologically confirm advanced and/or metastatic cancer , , limit single lesion , consider candidate curative surgery radiation therapy ) . 2 . Biopsy accessible lesion . 3 . Per cohort dose/volume , volume lesion inject must 3x volume injectate . 4 . Subjects complete acceptable therapy curative potential current standard care respective disease . 5 . Recovered toxicity ( ≤ Grade 1 ) relate prior therapy except alopecia . 6 . 1 measurable evaluable lesion ; ≥ 1.8 cm diameter cohort 1 ( see Table 10 ) ; injection biopsy accessible . 7 . Age ≥18 year . 8 . ECOG performance status ( PS ) 02 . 9 . Organ marrow function define : Absolute granulocyte count ≥ 1,500/mm^3 Platelets ≥ 100,000/mm^3 Total bilirubin ≤ 1.5x institutional ULN Creatinine ≤ 2.0 mg/dL 10 . Ability understand willingness sign write informed consent document include permission pre Days 1 2 post injection biopsy Day 8 inject lesion excision . 11 . Negative pregnancy test . 1 . Surgery involve general anesthesia , chemotherapy , radiotherapy , immunotherapy within 3 week prior enter study . 2 . Patient must receive investigational agent within 4 week prior study entry . 3 . Patients know brain metastasis unless treated whole brain radiation stable &gt; /= 2 month treat stereotactic radiotherapy stable &gt; /=1 month . 4 . Short term ( &lt; 30 day ) concurrent systemic steroid ≤0.125 mg/kg prednisone per day ( maximum 7.5 mg/day ) bronchodilator ( inhaled steroid ) permit ; steroid regimen and/or immunosuppressive exclude . 5 . Prior malignancy ( exclude nonmelanoma carcinomas skin ) unless remission &gt; /= 2 year . 6 . Kaposi 's Sarcoma . 7 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 8 . Patients pregnant nursing . 9 . Patients know HIV . 10 . Patients chronic Hepatitis B C infection . 11 . Patients uncontrolled disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Melanoma</keyword>
</DOC>